Good Tysabri performance fails to raise analysts' hopes for Elan
This article was originally published in Scrip
Elan's revenue continued its rapid growth in the third quarter, increasing by 53% to $270.1 million. Another strong performance by its multiple sclerosis and Crohn's disease treatment Tysabri (natalizumab), contributed $164.5 million (+159%) to Elan's total revenue. Tysabri's total in-market net sales increased by 154% to $237 million.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.